Chemists have developed a revolutionary new way to manufacture natural chemicals by clipping smaller molecules together like Lego. They have used the new method to assemble a scarce anti-inflammatory drug with potential to treat cancer and malaria, pseudopterosin.
“We took small molecules and clipped them together like Lego,” said lead researcher Professor Michael Sherburn, from the Research School of Chemistry.
“The building blocks are carefully designed in such a way that the first reaction generates a product perfectly primed for the second. It’s quite magical. This means you can efficiently build large and complex molecules.”
Medicines of this type have traditionally been made in a cumbersome way. Chemists take a related molecule and renovate it. This is a lengthy process, with unwanted structural features being ripped out and replaced.
“This leads to a lot of waste,” Professor Sherburn said.
The group trialed their innovative new method by making pseudopterosin, a powerful anti-inflammatory and analgesic drug, which is currently only available in tiny quantities extracted from fan coral found in the Bahamas.
The work began as blue-sky research, with the researchers trying to work out a way to make supposedly impossible molecules of cross-conjugated hydrocarbons.
Before trying the experiments the team ran simulations on the Raijin supercomputer, which indicated that their method had potential.
“Ours is an empowering and enabling technique, allowing a smarter and faster way to make important substances,” said Dr Chris Newton, who did the research in the laboratory as a PhD student.
The Latest on: Manufacturing new drugs
[google_news title=”” keyword=”Manufacturing new drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Manufacturing new drugs
- Pfizer fleshes out oncology strategy, targeting 8 blockbuster cancer drugs by 2030on February 29, 2024 at 1:42 pm
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | ...
- India's Suven Pharma, Cohance merge to boost contract drug manufacturing serviceson February 29, 2024 at 7:36 am
Indian contract drug manufacturer Suven Pharmaceuticals (SUVH.NS), opens new tab said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its ...
- Oprah Winfrey to exit WeightWatchers board, a blow as weight-loss drugs surgeon February 29, 2024 at 4:05 am
Winfrey leaves as weight-loss firms grapple with the rise in injectable drugs like Ozempic and Wegovy. WeightWatchers’ shares fell 27 percent after the news.
- US FDA chief very concerned about fake weight loss drugson February 28, 2024 at 6:42 pm
U.S. Food and Drug Administration Commissioner Dr. Robert Califf said on Wednesday that he is very concerned about the prevalence of compounded and fake versions of highly in demand new weight loss ...
- Viking Weight Loss Drug Targets Ozempic And Mounjaro Makers’ Supremacy — What To Knowon February 28, 2024 at 7:11 am
Viking Therapeutics’ stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisk’s Wegovy and ...
- Drugs, stolen figurine found after Schenectady stop, troopers sayon February 28, 2024 at 6:46 am
Drugs and a stolen concrete figuring were found after a traffic stop in Schenectady last week, New York State Police said Tuesday. The stop also involved a brief foot pursuit before the driver was ...
- The pet drugs vets are now prescribing look a lot more like human medicationson February 27, 2024 at 9:38 pm
New drug treatment options are coming for cats and dogs as the divide between animal and human health is starting to narrow.
- A New Generation of Drug Therapies Requires New Business Strategieson February 27, 2024 at 5:15 am
The shift to advanced therapeutic modalities (ATMs) promises to change the nature of competition in the pharmaceuticals industry. ATMs include engineered cell therapies that reprogram cells to fight ...
- Bristol Myers blueprints $400M Ireland expansion with plans to add sterile drug firepower and hire 350on February 26, 2024 at 7:45 am
BMS is plotting a $400-million SDP investment at its Dublin 15 Cruiserath campus in Ireland, which will be used to crank out existing medicines and serve as a “launch excellence facility” for pipeline ...
- BMS Invests $400M in Ireland Campus for New Sterile Drug Product Facilityon February 25, 2024 at 3:59 pm
Adding to the existing biologic manufacturing operations for bulk drug substance, this new investment is expected to significantly expand manufacturing and laboratory capacity in Cruiserath, as the ...
via Bing News